SCHEMBL143073

SCHEMBL143073

COc1ccc2nc(Nc3cc(C(F)(F)c4ccc(F)cc4)nc(N[C@H]4CC[C@H](N)CC4)n3)sc2c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 10/20 0.85
ITK Q08881 10/20 0.85
AURKB Q96GD4 8/20 0.85
MEN1 O00255 5/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
KMT2A Q03164 5/20 0.44
SCD O00767 1/20 0.44
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
GFER P55789 1/20 0.42
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
GALR2 O43603 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143074 1.00 LCK (0.85) LCKITKAURKBMEN1NPC1
SCHEMBL143617 0.92 LCK (1.00) LCKITKAURKBMEN1NPC1
SCHEMBL143616 0.92 LCK (1.00) LCKITKAURKBMEN1NPC1
SCHEMBL144163 0.84 LCK (0.84) LCKITKAURKBMEN1NPC1
SCHEMBL144162 0.84 LCK (0.84) LCKITKAURKBMEN1NPC1
SCHEMBL139891 0.81 ITK (0.81) LCKITKAURKBHCRTR1HCRTR2
SCHEMBL139892 0.81 ITK (0.81) LCKITKAURKBHCRTR1HCRTR2
SCHEMBL139967 0.81 ITK (0.81) LCKITKAURKB
SCHEMBL139966 0.81 ITK (0.81) LCKITKAURKB
SCHEMBL140694 0.81 LCK (0.65) LCKITKAURKBMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.